Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423

Robert T Dorr, Lee Wisner, Betty K. Samulitis, Terry H Landowski, William A. Remers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Preclinical studies evaluated the anti-tumor activity and mechanism of action of AMP423, a naphthyl derivative of 2-cyanoaziridine-1- carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon. Methods: The cytotoxic potency was evaluated in vitro against a variety of human cancer cell lines. Mechanism-of-action studies were performed in the human 8226/S myeloma cell line and its imexon-resistant variant, 8226/IM10. In vivo activity was evaluated against human myeloma and lymphoma xenografts in SCID mice. Pharmacokinetics and toxicology were investigated in non-tumor-bearing mice. Results: The 72-h IC 50s for all cell types ranged from 2 to 36 μM, across a wide variety of human cancer cell lines. AMP423 was active in SCID mice bearing 8226/S myeloma and SU-DHL-6 B-cell lymphoma tumors, with a median tumor growth delay (T-C) of 21 days (P = 0.0002) and 5 days (P = 0.004), respectively, and a median tumor growth inhibition (T/C) of 33.3% (P = 0.03) and 82% (P = 0.01), respectively. In non-tumor-bearing mice, AMP423 was not myelosuppressive. Mechanistic studies show that AMP423's mode of cell death is a mixture of necrosis and apoptosis, with generation of reactive oxygen species, inhibition of protein synthesis, and a decrease in reduced sulfhydryl levels, but no alkylation of nucleophiles. Unlike its structural analog imexon, which causes cell cycle arrest in G 2/M, AMP423 induces the accumulation of cells in S-phase. Conclusions: AMP423 has pro-oxidant effects similar to imexon, has greater cytotoxic potency in vitro, and has anti-tumor activity in hematologic tumors in vivo.

Original languageEnglish (US)
Pages (from-to)1039-1049
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Volume69
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Tumors
Bearings (structural)
Derivatives
Cells
Neoplasms
Reactive Oxygen Species
SCID Mice
Cell Line
Nucleophiles
Pharmacokinetics
Alkylation
Cell death
AMP423
Heterografts
B-Cell Lymphoma
Growth
Cell Cycle Checkpoints
S Phase
Toxicology
Apoptosis

Keywords

  • AMP423
  • Cyanoaziridine
  • Imexon
  • Preclinical
  • Pro-oxidant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423. / Dorr, Robert T; Wisner, Lee; Samulitis, Betty K.; Landowski, Terry H; Remers, William A.

In: Cancer Chemotherapy and Pharmacology, Vol. 69, No. 4, 04.2012, p. 1039-1049.

Research output: Contribution to journalArticle

Dorr, Robert T ; Wisner, Lee ; Samulitis, Betty K. ; Landowski, Terry H ; Remers, William A. / Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423. In: Cancer Chemotherapy and Pharmacology. 2012 ; Vol. 69, No. 4. pp. 1039-1049.
@article{55d47164d6ae401395af0b36d55d84ce,
title = "Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423",
abstract = "Purpose: Preclinical studies evaluated the anti-tumor activity and mechanism of action of AMP423, a naphthyl derivative of 2-cyanoaziridine-1- carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon. Methods: The cytotoxic potency was evaluated in vitro against a variety of human cancer cell lines. Mechanism-of-action studies were performed in the human 8226/S myeloma cell line and its imexon-resistant variant, 8226/IM10. In vivo activity was evaluated against human myeloma and lymphoma xenografts in SCID mice. Pharmacokinetics and toxicology were investigated in non-tumor-bearing mice. Results: The 72-h IC 50s for all cell types ranged from 2 to 36 μM, across a wide variety of human cancer cell lines. AMP423 was active in SCID mice bearing 8226/S myeloma and SU-DHL-6 B-cell lymphoma tumors, with a median tumor growth delay (T-C) of 21 days (P = 0.0002) and 5 days (P = 0.004), respectively, and a median tumor growth inhibition (T/C) of 33.3{\%} (P = 0.03) and 82{\%} (P = 0.01), respectively. In non-tumor-bearing mice, AMP423 was not myelosuppressive. Mechanistic studies show that AMP423's mode of cell death is a mixture of necrosis and apoptosis, with generation of reactive oxygen species, inhibition of protein synthesis, and a decrease in reduced sulfhydryl levels, but no alkylation of nucleophiles. Unlike its structural analog imexon, which causes cell cycle arrest in G 2/M, AMP423 induces the accumulation of cells in S-phase. Conclusions: AMP423 has pro-oxidant effects similar to imexon, has greater cytotoxic potency in vitro, and has anti-tumor activity in hematologic tumors in vivo.",
keywords = "AMP423, Cyanoaziridine, Imexon, Preclinical, Pro-oxidant",
author = "Dorr, {Robert T} and Lee Wisner and Samulitis, {Betty K.} and Landowski, {Terry H} and Remers, {William A.}",
year = "2012",
month = "4",
doi = "10.1007/s00280-011-1784-8",
language = "English (US)",
volume = "69",
pages = "1039--1049",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423

AU - Dorr, Robert T

AU - Wisner, Lee

AU - Samulitis, Betty K.

AU - Landowski, Terry H

AU - Remers, William A.

PY - 2012/4

Y1 - 2012/4

N2 - Purpose: Preclinical studies evaluated the anti-tumor activity and mechanism of action of AMP423, a naphthyl derivative of 2-cyanoaziridine-1- carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon. Methods: The cytotoxic potency was evaluated in vitro against a variety of human cancer cell lines. Mechanism-of-action studies were performed in the human 8226/S myeloma cell line and its imexon-resistant variant, 8226/IM10. In vivo activity was evaluated against human myeloma and lymphoma xenografts in SCID mice. Pharmacokinetics and toxicology were investigated in non-tumor-bearing mice. Results: The 72-h IC 50s for all cell types ranged from 2 to 36 μM, across a wide variety of human cancer cell lines. AMP423 was active in SCID mice bearing 8226/S myeloma and SU-DHL-6 B-cell lymphoma tumors, with a median tumor growth delay (T-C) of 21 days (P = 0.0002) and 5 days (P = 0.004), respectively, and a median tumor growth inhibition (T/C) of 33.3% (P = 0.03) and 82% (P = 0.01), respectively. In non-tumor-bearing mice, AMP423 was not myelosuppressive. Mechanistic studies show that AMP423's mode of cell death is a mixture of necrosis and apoptosis, with generation of reactive oxygen species, inhibition of protein synthesis, and a decrease in reduced sulfhydryl levels, but no alkylation of nucleophiles. Unlike its structural analog imexon, which causes cell cycle arrest in G 2/M, AMP423 induces the accumulation of cells in S-phase. Conclusions: AMP423 has pro-oxidant effects similar to imexon, has greater cytotoxic potency in vitro, and has anti-tumor activity in hematologic tumors in vivo.

AB - Purpose: Preclinical studies evaluated the anti-tumor activity and mechanism of action of AMP423, a naphthyl derivative of 2-cyanoaziridine-1- carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon. Methods: The cytotoxic potency was evaluated in vitro against a variety of human cancer cell lines. Mechanism-of-action studies were performed in the human 8226/S myeloma cell line and its imexon-resistant variant, 8226/IM10. In vivo activity was evaluated against human myeloma and lymphoma xenografts in SCID mice. Pharmacokinetics and toxicology were investigated in non-tumor-bearing mice. Results: The 72-h IC 50s for all cell types ranged from 2 to 36 μM, across a wide variety of human cancer cell lines. AMP423 was active in SCID mice bearing 8226/S myeloma and SU-DHL-6 B-cell lymphoma tumors, with a median tumor growth delay (T-C) of 21 days (P = 0.0002) and 5 days (P = 0.004), respectively, and a median tumor growth inhibition (T/C) of 33.3% (P = 0.03) and 82% (P = 0.01), respectively. In non-tumor-bearing mice, AMP423 was not myelosuppressive. Mechanistic studies show that AMP423's mode of cell death is a mixture of necrosis and apoptosis, with generation of reactive oxygen species, inhibition of protein synthesis, and a decrease in reduced sulfhydryl levels, but no alkylation of nucleophiles. Unlike its structural analog imexon, which causes cell cycle arrest in G 2/M, AMP423 induces the accumulation of cells in S-phase. Conclusions: AMP423 has pro-oxidant effects similar to imexon, has greater cytotoxic potency in vitro, and has anti-tumor activity in hematologic tumors in vivo.

KW - AMP423

KW - Cyanoaziridine

KW - Imexon

KW - Preclinical

KW - Pro-oxidant

UR - http://www.scopus.com/inward/record.url?scp=84859802410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859802410&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1784-8

DO - 10.1007/s00280-011-1784-8

M3 - Article

C2 - 22186884

AN - SCOPUS:84859802410

VL - 69

SP - 1039

EP - 1049

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -